Substantial work has been carried out in studying and targeting the DDR during conversion to CRPC [93,121], but targeting the critical components of the DDR (like ATR/ATM and their effector kinases) or DNA Repair pathways (like the use of PARP inhibitors) do not offer optimal targeted specificity to PCa cells. The gene discussed is ATR; the disease is posterior cortical atrophy.